AIM ImmunoTech Inc.
| Metric | FY2025 | FY2024 |
|---|---|---|
| Clinical treatment programs – US | $88K-48.2% | $170K |
| Total Revenues | $88K-48.2% | $170K |
| Production costs | $128K+312.9% | $31K |
| Research and development | $3.9M-36.7% | $6.2M |
| General and administrative | $7.7M-43.9% | $13.7M |
| Total Costs and Expenses | $11.8M-41.1% | $19.9M |
| Operating loss | -$11.7M+41.0% | -$19.8M |
| (Loss) gain on investments | $17K+118.3% | -$93K |
| Interest and other income | $3.2M-38.7% | $5.2M |
| Interest expense | -$812K-38.8% | -$585K |
| Issuance cost | -$433K | — |
| Loss on warrant issuance | -$4.0M | — |
| Change in fair value of warrants | -$272K+40.6% | -$458K |
| Loss from sale of income tax operating losses | -$1.6M | — |
| Net Loss | -$14.0M+19.4% | -$17.3M |
| Basic loss per share | -$8620.00+72.1% | -$30920.00 |
| Diluted loss per share | -$8620.00+72.1% | -$30920.00 |
| Weighted average shares outstanding basic | 1.62B+189.0% | 560.2M |
| Weighted average shares outstanding diluted | 1.62B+189.0% | 560.2M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
AIM ImmunoTech increases stockholder equity by $11.9 million to $2.1 million and extends promissory note maturity to June 2027
“This amendment enhances our capital allocation flexibility at an important stage for the Company as we remain focused on executing our clinical and operational priorities.”
No Form 4 transactions on record.
Informational purposes only, not investment advice.